The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with and without leuprolide acetate**Supported in part by TAP Pharmaceuticals, Abbott Park, Illinois.

1990 ◽  
Vol 54 (1) ◽  
pp. 27-31 ◽  
Author(s):  
Kevin E. Bachus ◽  
Claude L. Hughes ◽  
A.F. Haney ◽  
William C. Dodson
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Luteal Phase ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Leuprolide Acetate ◽  
Human Menopausal Gonadotropin ◽  
Ovary Syndrome

scholarly journals Application of Pulsed Rhythmic Drug Administration to Ovulation Induction Therapy in PCOS Patients with Clomiphene-Resistance: a Retrospective Research

2021 ◽  
Author(s):  
Xinyue Zhang ◽  
Aiyan Zheng ◽  
Jihong Yang ◽  
Ting Feng ◽  
Yan Zhang ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Pregnancy Rate ◽  
Therapeutic Effect ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Induction Treatment ◽  
Human Menopausal Gonadotropin ◽  
Ovary Syndrome ◽  
Clomiphene Resistance ◽  
Administration Protocol

AbstractThere is currently a dispute over the choice of ovulation induction treatment for infertile women with polycystic ovary syndrome (PCOS). The objective of this study is to compare the therapeutic effect of pulsed rhythmic administration protocol (PRAP) with conventional letrozole + human menopausal gonadotropin (HMG) in patients with clomiphene-resistance polycystic ovary syndrome (PCOS). A retrospective analysis of 821 intrauterine insemination (IUI) cycles between January 2015 and January 2020 was performed. Of these, 483 cycles were treated with a pulsed rhythmic administration protocol (PRAP), and 338 cycles were treated with conventional letrozole + HMG protocol (LHP). The therapeutic effect of the two protocols has been compared. The pregnancy rate was 18.07% in the LHP and 27.07% in the PRAP. The ongoing pregnancy rate in LHP was 14.46% and in PRAP was 22.73%. The research suggests that PRAP is more effective than LHP and could be an adequate ovulation induction strategy for the IUI cycle of patients with clomiphene-resistance PCOS.

Sign in / Sign up

Export Citation Format

Share Document